lifestyle.marketresearchjournals.com

Author: GRAIL, Inc.

GRAIL to Present New Data From NHS-Galleri and PATHFINDER 2 at 2026 ASCO Annual Meeting

April 21, 2026
GRAIL Announces Integration of the Galleri® Test into Epic Electronic Health Record Platform to Expand Access Nationwide

April 7, 2026
GRAIL Announces Retirement of CEO Bob Ragusa and Appointment of Josh Ofman, MD, MSHS, as Successor

March 12, 2026
GRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

March 2, 2026
GRAIL to Present at the TD Cowen 46th Annual Health Care Conference

February 24, 2026
Landmark NHS-Galleri Trial Demonstrates a Substantial Reduction in Stage IV Cancer Diagnoses, Increased Stage I and II Detection of Deadly Cancers, and Four-Fold Higher Cancer Detection Rate

February 20, 2026
GRAIL Reports Fourth Quarter and Full Year 2025 Financial Results

February 19, 2026
GRAIL to Announce Fourth Quarter and Full Year 2025 Financial Results

February 16, 2026
GRAIL Submits FDA Premarket Approval Application for the Galleri® Multi-Cancer Early Detection Test

January 29, 2026
GRAIL to Present at the 44th Annual J.P. Morgan Healthcare Conference

December 16, 2025